Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 3/20 | 0.58 |
| ▸ | ARG1 | P05089 | 1/20 | 0.55 |
| ▸ | ARG2 | P78540 | 1/20 | 0.55 |
| ▸ | NOS1 | P29475 | 2/20 | 0.53 |
| ▸ | NOS3 | P29474 | 1/20 | 0.53 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.49 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.49 |
| ▸ | BHMT | Q93088 | 3/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2425454 | 1.00 | NOS2 (0.58) | NOS2ARG1ARG2NOS1NOS3 | |
| SCHEMBL11572921 | 0.98 | NOS2 (0.57) | NOS2ARG1ARG2NOS1NOS3 | |
| SCHEMBL10073278 | 0.98 | NOS2 (0.57) | NOS2ARG1ARG2NOS1NOS3 | |
| SCHEMBL29941026 | 0.98 | NOS2 (0.57) | NOS2ARG1ARG2NOS1NOS3 | |
| SCHEMBL3082545 | 0.98 | NOS2 (0.57) | NOS2ARG1ARG2NOS1NOS3 | |
| SCHEMBL3082543 | 0.98 | NOS2 (0.57) | NOS2ARG1ARG2NOS1NOS3 | |
| SCHEMBL8612866 | 0.98 | NOS2 (0.57) | NOS2ARG1ARG2NOS1NOS3 | |
| SCHEMBL9544550 | 0.98 | NOS2 (0.57) | NOS2ARG1ARG2NOS1NOS3 | |
| SCHEMBL20553470 | 0.98 | NOS2 (0.57) | NOS2ARG1ARG2NOS1NOS3 | |
| SCHEMBL11572914 | 0.98 | NOS2 (0.57) | NOS2ARG1ARG2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2186512-A1 | USE OF ALLYLCYSTEINE OR ITS ANALOGS AND PHARMACEUTICAL COMPOSITION THREROF | Fudan University (CN) | 2010-05-19 | — | — | EP | claimed |
| US-4721705-A | Skin treatment compositions | Chemish Adviesbureau Drs. J.C.P. Schreuder B.V. (NL) | 1988-01-26 | — | — | US | claimed |
| US-20250327074-A1 | THE RARE CODON RECODING PLATFORM FOR NONCANONICAL AMINO ACIDS INCORPORATION IN MAMMALIAN CELLS | SHAOXING INSTITUTE, ZHEJIANG UNIVERSITY (CN) | 2025-10-23 | — | — | US | disclosed |
| EP-2937334-A1 | PROPIONIC ACIDS, PROPIONIC ACID ESTERS, AND RELATED COMPOUNDS | Promentis Pharmaceuticals, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-8815905-B2 | Propionic acids, propionic acid esters, and related compounds | PROMENTIS PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8623919-B2 | Method of synthesizing S-allyl-cysteine analogues and their therapeutic application in treating myocardial infarction | FUDAN UNIVERSITY (CN) | 2014-01-07 | — | — | US | disclosed |
| EP-2545033-A2 | PROPIONIC ACIDS, PROPIONIC ACID ESTERS, AND RELATED COMPOUNDS | Promentis Pharmaceuticals, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2011112535-A2 | PROPIONIC ACIDS, PROPIONIC ACID ESTERS, AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110224156-A1 | Propionic Acids, Propionic Acid Esters, and Related Compounds | ALBANY MOLECULAR RESEARCH, INC. | 2011-09-15 | — | — | US | disclosed |
| EP-2186512-A1 | USE OF ALLYLCYSTEINE OR ITS ANALOGS AND PHARMACEUTICAL COMPOSITION THREROF | Fudan University (CN) | 2010-05-19 | — | — | EP | disclosed |
| US-20090036534-A1 | Method Of Synthesizing S-Allyl-Cysteine Analogues And Their Therapeutic Application In Treating Myocardial Infarction | FUDAN UNIVERSITY (CN) | 2009-02-05 | — | — | US | disclosed |
| US-5472698-A | Mixture of (N-acetyl)-L-serine, N-acetylcysteine and alpha-lipoic acid which promotes ceramide production in skin cells | ELIZABETH ARDEN CO., DIVISION OF CONOPCO, INC. (US) | 1995-12-05 | — | — | US | disclosed |
| US-4721705-A | Skin treatment compositions | Chemish Adviesbureau Drs. J.C.P. Schreuder B.V. (NL) | 1988-01-26 | — | — | US | disclosed |
| US-4721705-A | Skin treatment compositions | Chemish Adviesbureau Drs. J.C.P. Schreuder B.V. (NL) | 1988-01-26 | — | — | US | disclosed |
| US-4642355-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1987-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224156-A1 | Propionic Acids, Propionic Acid Esters, and Related Compounds | PCCA, PC, PMP22 | NOS2 4503/4885ARG1 2935/4885ARG2 1635/4885 |
| US-20090036534-A1 | Method Of Synthesizing S-Allyl-Cysteine Analogues And Their Therapeutic Application In Treating Myocardial Infarction | SRM, SMS, SCLY | NOS2 1892/4885ARG1 2914/4885ARG2 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.